Cipla gets approval from SAHPRA for first-line triple-combination antiretroviral

12 Sep 2018 Evaluate

South African Health Products Regulatory Authority (SAHPRA) has approved Cipla’s latest first-line triple-combination antiretroviral (ARV) treatment for HIV. The new combination medicine commonly referred to as TLD, is a combination of tenofovir (TDF), lamivudine (3TC) and dolutegravir (DTG).

In future, TLD will be manufactured at Cipla’s facilities in Durban and Uganda, reinforcing Cipla’s commitment to produce medicines in Africa for Africa and ensuring more affordable treatment for patients.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1466.15 5.55 (0.38%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×